Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Nov;38(11):2545–2552. doi: 10.1128/aac.38.11.2545

Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.

M Sarić 1, A B Clarkson Jr 1
PMCID: PMC188239  PMID: 7872745

Abstract

Pneumocystis carinii pneumonia (PCP) can be treated with eflornithine (difluoromethylornithine, DFMO, Ornidyl), a competitive irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme for polyamine biosynthesis. Because ODC has been reported to be absent from P. carinii, it has been assumed that eflornithine affects P. carinii only indirectly, by affecting host polyamine biosynthesis. If this is true, then improvements in the selectivity of antipolyamine therapy for PCP would be limited. Since the presence of ODC in P. carinii is an important issue, a new search for this enzyme was made. Not only were initial assays negative, but P. carinii extract reduced the background catalytic action of pyridoxal-5'-phosphate, the coenzyme required by the enzyme. This suggested the presence of an inhibitor, which was further supported by the observation that a P. carinii extract could suppress a source of known ODC activity. The inhibitory activity could be removed by a desalting column or by dialysis, allowing detection of P. carinii ODC. Indirect evidence indicates that the inhibition is only apparent and is caused by unlabeled ornithine in the extract of P. carinii which interferes with the radiolabel-based assay system. P. carinii and host ODCs respond differently to changes in pH. P. carinii ODC is much less susceptible to inhibition by eflornithine than host ODC. The presence of ODC in P. carinii suggests that P. carinii ODC is the target of eflornithine and that P. carinii ODC may have sufficiently specific properties that inhibitors with improved selectivity against P. carinii ODC could be identified.

Full text

PDF
2545

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bowling M. C., Smith I. M., Wescott S. L. A rapid staining procedure for Pneumocystis carinii. Am J Med Technol. 1973 Jul;39(7):267–268. [PubMed] [Google Scholar]
  2. Boylan C. J., Current W. L. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals. Infect Immun. 1992 Apr;60(4):1589–1597. doi: 10.1128/iai.60.4.1589-1597.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarkson A. B., Jr, Williams D. E., Rosenberg C. Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Aug;32(8):1158–1163. doi: 10.1128/aac.32.8.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cushion M. T., Ruffolo J. J., Linke M. J., Walzer P. D. Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Exp Parasitol. 1985 Aug;60(1):43–54. doi: 10.1016/s0014-4894(85)80021-7. [DOI] [PubMed] [Google Scholar]
  6. Garofalo J., Bacchi C. J., McLaughlin S. D., Mockenhaupt D., Trueba G., Hutner S. H. Ornithine decarboxylase in Trypanosoma brucei brucei: evidence for selective toxicity of difluoromethylornithine. J Protozool. 1982 Aug;29(3):389–394. doi: 10.1111/j.1550-7408.1982.tb05418.x. [DOI] [PubMed] [Google Scholar]
  7. Gilman T. M., Paulson Y. J., Boylen C. T., Heseltine P. N., Sharma O. P. Eflornithine treatment of Pneumocystis carinii pneumonia in AIDS. JAMA. 1986 Oct 24;256(16):2197–2198. [PubMed] [Google Scholar]
  8. Golden J. A., Sjoerdsma A., Santi D. V. Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome. West J Med. 1984 Nov;141(5):613–623. [PMC free article] [PubMed] [Google Scholar]
  9. Justice A. C., Feinstein A. R., Wells C. K. A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med. 1989 May 25;320(21):1388–1393. doi: 10.1056/NEJM198905253202106. [DOI] [PubMed] [Google Scholar]
  10. Lipschik G. Y., Masur H., Kovacs J. A. Polyamine metabolism in Pneumocystis carinii. J Infect Dis. 1991 May;163(5):1121–1127. doi: 10.1093/infdis/163.5.1121. [DOI] [PubMed] [Google Scholar]
  11. Paulson Y. J., Gilman T. M., Heseltine P. N., Sharma O. P., Boylen C. T. Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Chest. 1992 Jan;101(1):67–74. doi: 10.1378/chest.101.1.67. [DOI] [PubMed] [Google Scholar]
  12. Pegg A. E., McCann P. P. Polyamine metabolism and function. Am J Physiol. 1982 Nov;243(5):C212–C221. doi: 10.1152/ajpcell.1982.243.5.C212. [DOI] [PubMed] [Google Scholar]
  13. Pesanti E. L., Bartlett M. S., Smith J. W. Lack of detectable activity of ornithine decarboxylase in Pneumocystis carinii. J Infect Dis. 1988 Nov;158(5):1137–1138. doi: 10.1093/infdis/158.5.1137. [DOI] [PubMed] [Google Scholar]
  14. Smith D., Davies S., Nelson M., Youle M., Gleeson J., Gazzard B. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. AIDS. 1990 Oct;4(10):1019–1021. doi: 10.1097/00002030-199010000-00012. [DOI] [PubMed] [Google Scholar]
  15. Vöhringer H. F., Arastéh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet. 1993 May;24(5):388–412. doi: 10.2165/00003088-199324050-00004. [DOI] [PubMed] [Google Scholar]
  16. Wakefield A. E., Pixley F. J., Banerji S., Sinclair K., Miller R. F., Moxon E. R., Hopkin J. M. Detection of Pneumocystis carinii with DNA amplification. Lancet. 1990 Aug 25;336(8713):451–453. doi: 10.1016/0140-6736(90)92008-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES